Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S119000
Reexamination Certificate
active
08003663
ABSTRACT:
The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl) (methyl)amino]octanoyl}amino)benzamide, whose formula isor a salt thereof, such as the monohydrochloride salt thereof.The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).
REFERENCES:
patent: 3200123 (1965-08-01), Richardson et al.
patent: 2008/0058369 (2008-03-01), Allen et al.
patent: 2009/0318494 (2009-12-01), Allen et al.
patent: 2009/0325952 (2009-12-01), Allen et al.
patent: 21 01 691 (1972-03-01), None
patent: 1 099 701 (2001-05-01), None
patent: WO 96/40640 (1996-12-01), None
patent: WO 97/48683 (1997-12-01), None
patent: WO 98/41508 (1998-09-01), None
patent: WO 00/69849 (2000-11-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/62737 (2001-08-01), None
patent: WO 02/08221 (2002-01-01), None
patent: WO 2005/058892 (2005-06-01), None
patent: WO 2005/090348 (2005-09-01), None
patent: WO 2005/090353 (2005-09-01), None
patent: WO 2007/036733 (2007-04-01), None
Szallasi, A., et. al, “Vanilloid (Capsaicin) Receptors and Mechanisms” Pharmacological Reviews, Williams and Wilkins Inc., Baltimore, MD, US, vol. 51, No. 2, 1999, pp. 159-211, XP001105620, ISSN: 0031-6997.
Wai, N. Chan, et al.: “Evaluation of a series of anticonvulsant 1,2,3,4-tetrahydroisoquinolinolinyl-benzamides”, BioOrg. Med. Chem., vol. 8, 2000, pp. 2085-2094, XP002239649.
Hishashi shinkai: “4-aminoquinolines: novel nociceptin antagonists with analgesic activity” J. Med. Chem., vol. 43, No. 24, 2000, pp. 4667-4677, XP002239650.
Patent Abstracts of Japan, vol. 1999, No. 2, Feb. 26, 1999 & JP 10 291988 A (Fujisawa Pharmaceut Co. Ltd), Nov. 4, 1998.
J. Jaen et al. “Kyurenic acid derivatives inhibit the binding of Nerve Growth Factor (NGF) to the Low-Affinity p75 NGF receptor” J. Med. Chem., vol. 38, No. 22, 1995, pp. 4439-4445, XP002239651.
Formulary, Rolfumalist: A new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease, (2010), pp. 1-10.
Takizawa, et al., Recent patents on inflammation & Allergy drug discovery (2007), 1, pp. 13-19.
Patani, et al. Chem.. Rev. (1996), 96 pp. 3147-3176.
Non Final Office Action dated Jan. 19, 2011; U.S. Appl. No. 12/375,685.
U.S. Appl. No. 12/375,685, filed Jan. 2009, Allen et al.
Allen David George
Barnett Rodger Phillip
Chudasama Reshma Manesh
Day Caroline Jane
Edlin Christopher David
Furman Theodore R.
Glaxo Group Limited
Morris Patricia L
Stein Nora L.
LandOfFree
Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718320